Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection

Pharmacotherapy

Volumn 35, Issue 2, 2015, Pages 119-126

  Pettit, Natasha N ^a,b   Depestel, Daryl D ^a,b   Fohl, Alexander L ^a,b   Eyler, Rachel ^a,b   Carver, Peggy L ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

biologic availability; intestinal absorption; vancomycin retention enemas

Indexed keywords

ENEMA; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CLOSTRIDIUM DIFFICILE INFECTION; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; CREATININE CLEARANCE; CROHN DISEASE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MEGADOSE; ENEMA DEVICE; FEMALE; GRAFT VERSUS HOST REACTION; HEMODIALYSIS; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRESCHOOL CHILD; PROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; ULCERATIVE COLITIS; AGED; CLOSTRIDIUM INFECTIONS; ISOLATION AND PURIFICATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; UNIVERSITY HOSPITAL; VERY ELDERLY;

ACADEMIC MEDICAL CENTERS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; VANCOMYCIN;

EID: 84923300117     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1538     Document Type: Article

References (35)

1. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 5: 431-55.
2. Fekety R, Silva J, Kauffman C, Buggy B, Deery HG,. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989; 1: 15-9.
3. Deneve C, Janoir C, Poilane I, Fantinato C, Collignon A,. New trends in Clostridium difficile virulence and pathogenesis. Int J Antimicrob Agents 2009; 33: S24-8.
4. Bryan CS, White WL,. Safety of oral vancomycin in functionally anephric patients. Antimicrob Agents Chemother 1978; 4: 634-5.
5. Griffith RS,. Vancomycin: continued clinical studies. In:, H. Welch, and, F. Marti-Ibaney, eds. Antibiotics annual: 1956-1957. New York, NY: Medical Encyclopedia, Inc., 1957: 118-22.
6. Geraci JE, Heilman FR, Nichols DR, Ross GT, Wellman WE,. Some laboratory and clinical experiences with a new antibiotic, vancomycin. Proc Staff Meet Mayo Clin 1956; 21: 564-82.
7. Pogue JM, DePestel DD, Kaul DR, Khaled Y, Frame DG,. Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract. Transpl Infect Dis 2009; 5: 467-70.
8. Donskey C, Miller M, Crook DW, Sears P, Gorbach SL,. Plasma vancomycin concentrations in patients with Clostridium difficile infection taking oral vancomycin [abstract]. Clin Microbiol Infect 2012.
9. Armstrong CJ, Wilson TS,. Systemic absorption of vancomycin. J Clin Pathol 1995; 7: 689.
10. Brouwer DM, Corallo CE, Coutsouvelis J,. Systemic absorption of low-dose oral vancomycin. J Pharm Pract Res 2005; 3: 222-3.
11. Matzke GR, Halstenson CE, Olson PL, Collins AJ, Abraham PA,. Systemic absorption of oral vancomycin in patients with renal insufficiency and antibiotic-associated colitis. Am J Kidney Dis 1987; 5: 422-5.
12. Garrett A, Murphy JE,. Systemic absorption of orally administered vancomycin. Atlanta, GA: Georgia J Hosp Pharmacy, 1991: 2.
13. Hirata S, Matoba M, Izumi S, et al. Elevated serum vancomycin concentrations after oral administration in a hemodialysis patient with Pseudomembranous colitis. Jpn J Clin Pharmacol Therapeut 2003; 3: 87-90.
14. Pasic M, Carrel T, Opravil M, Mihaljevic T, von Segesser L, Turina M,. Systemic absorption after local intracolonic vancomycin in pseudomembranous colitis. Lancet 1993; 8868: 443.
15. Dudley MN, Quintiliani R, Nightingale CH, Gontarz N,. Absorption of vancomycin. Ann Intern Med 1984; 1: 144.
16. Spitzer PG, Eliopoulos GM,. Systemic absorption of enteral vancomycin in a patient with pseudomembranous colitis. Ann Intern Med 1984; 4: 533-4.
17. Tedesco F, Markham R, Gurwith M, Christie D, Bartlett JG,. Oral vancomycin for antibiotic-associated Pseudomembranous colitis. Lancet 1978; 8083: 226-8.
18. Aradhyula S, Manian FA, Hafidh SA, Bhutto SS, Alpert MA,. Significant absorption of oral vancomycin in a patient with Clostridium difficile colitis and normal renal function. South Med J 2006; 5: 518-20.
19. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 4: 521-8.
20. Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM,. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 2006; 4: 699-704.
21. Tsuji BT, Rybak MJ, Lau KL, Sakoulas G,. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2007; 3: 1089-91.
22. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 1: 31-41.
23. Gelfand MS, Cleveland KO, Memon KA,. Detection of vancomycin levels in patients receiving telavancin but not vancomycin. J Antimicrob Chemother 2012; 2: 508-9.
24. Mickey RM, Greenland S,. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989; 1: 125-37.
25. Thompson CM Jr, Long SS, Gilligan PH, Prebis JW,. Absorption of oral vancomycin-possible associated toxicity. Int J Pediatr Nephrol 1983; 1: 1-4.
26. ViroPharma. Vancocin (vancomycin) capsules package insert. Exton, PA; 2011.
27. Launay-Vacher V, Izzedine H, Mercadal L, Deray G,. Clinical review: use of vancomycin in haemodialysis patients. Crit Care 2002; 4: 313-6.
28. Chaijamorn W, Jitsurong A, Wiwattanawongsa K, Wanakamanee U, Dandecha P,. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Int J Antimicrob Agents 2011; 2: 152-6.
29. Gonzales M, Pepin J, Frost EH, et al. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis 2010; 10:363.
30. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB,. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 3: 302-7.
31. Bergeron L, Boucher FD,. Possible red-man syndrome associated with systemic absorption of oral vancomycin in a child with normal renal function. Ann Pharmacother 1994; 5: 581-4.
32. Cadle RM, Mansouri MD, Darouiche RO,. Vancomycin-induced elevation of liver enzyme levels. Ann Pharmacother 2006; 6: 1186-9.
33. Bailey P, Gray H,. An elderly woman with "Red Man Syndrome" in association with oral vancomycin therapy: a case report. Cases J 2008; 1: 111.
34. Osawa R, Kaka AS,. Maculopapular rash induced by oral vancomycin. Clin Infect Dis 2008; 6: 860-1.
35. Yamazaki S, Nakamura H, Yamagata S, et al. Unexpected serum level of vancomycin after oral administration in a patient with severe colitis and renal insufficiency. Int J Clin Pharmacol Ther 2009; 11: 701-6.